Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.58 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.54 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.54 |
| ▸ | CALCR | P30988 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.53 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.53 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.52 |
| ▸ | MC4R | P32245 | 1/20 | 0.52 |
| ▸ | TFPI | P10646 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934272 | 0.91 | NMUR2 (0.57) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL30933140 | 0.91 | OPRD1 (0.55) | NMUR2NMUR1RAMP3CALCRNTSR1 | |
| SCHEMBL31433237 | 0.89 | NMUR2 (0.61) | NMUR2NMUR1CXCR4RAMP3CALCR | |
| SCHEMBL30567748 | 0.89 | NMUR2 (0.65) | NMUR2NMUR1KEAP1TFPI | |
| SCHEMBL30414371 | 0.88 | OPRD1 (0.57) | NMUR2NMUR1RAMP3CALCRAPLNR | |
| SCHEMBL31472965 | 0.88 | NMUR2 (0.59) | NMUR2NMUR1IL23RNTSR1TFPI | |
| SCHEMBL31603932 | 0.88 | NMUR2 (0.61) | NMUR2NMUR1RAMP3CALCRAPLNR | |
| SCHEMBL30933102 | 0.86 | NMUR2 (0.53) | NMUR2NMUR1KEAP1NTSR1OPRD1 | |
| SCHEMBL30933101 | 0.86 | REN (0.54) | NMUR2NMUR1APLNROPRD1 | |
| SCHEMBL21571000 | 0.86 | NMUR2 (0.52) | NMUR2NMUR1IL23RRAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102332-A1 | NERVE AND TUMOR HOMING AGENTS AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12048732-B2 | Methods of treating breast cancer | Blaze Bioscience, Inc. (US) | 2024-07-30 | — | — | US | disclosed |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | disclosed |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. | 2023-02-09 | — | — | US | disclosed |
| EP-4076500-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | Blaze Bioscience, Inc. (US) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | CHLSN, SLC47A1, CLSPN | NMUR2 1904/4885NMUR1 1551/4885CXCR4 709/4885 |
| US-20230037660-A1 | METHODS OF TREATING VASCULAR LESIONS AND MALFORMATIONS | FLT4, FLT1, KDR | NMUR2 903/4885NMUR1 705/4885CXCR4 369/4885 |
| US-12048732-B2 | Methods of treating breast cancer | BRCA1, HUNK, MLEC | NMUR2 1088/4885NMUR1 719/4885CXCR4 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.